RxDoctor Payments Data

Kenneth Goldman, MD

General Surgery · Plainsboro, NJNPI 1821085937

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,739 of the $4,239 with a category attached, or 64.6%. 22 manufacturers reported payments, led by Medtronic at 57.2% of the total. Reporting peaked in 2019 at $2,003 and has fallen 88.0% since, to $240 in 2025.

$4,239in general payments, 2019–2025

Across 83 payments — averaging $51.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Bard Peripheral Vascular, Inc.$503
  • Boston Scientific$288
  • Johnson & Johnson$210
  • Smith+Nephew$172
  • Baxter Healthcare$112
  • plus $530 from 16 others

What the payments were for

  • Speaking & faculty fees$1,50035%
  • Food & beverage$2,73965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,239 in reported general payments places this provider in the 80th percentile of 39 general surgery providers in New Jersey.

See all general surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,564,642
Medicare patients
1,198
Services billed
6,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban24$29,640
EliquisApixaban25$27,001
SantylCollagenase Clostridium Hist.40$18,907
Cilostazol68$3,077
Fluocinonide49$2,165
Clobetasol Propionate23$1,315
Cefadroxil54$629
ClopidogrelClopidogrel Bisulfate26$526
Doxycycline Hyclate18$339
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$210$29,64024 claims
PfizerEliquis$28$27,00125 claims
Smith+NephewSantyl$172$18,90740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 39 general surgery providers in New Jersey.

Other general surgery in Plainsboro

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →